Disclosed herein, are recombinant polypeptides comprising a first domain, wherein the first domain comprises an epitope of a coronavirus or wherein the first domain is a moiety that is capable of specifically binding a coronavirus antigen; a linker; and a second domain, wherein the second domain is a moiety that is capable of specifically binding an antigen on the surface of a red blood cell. Also, disclosed herein are methods for detecting anti-coronavirus antibodies, one or more coronavirus antigens, or one or more coronavirus virions by mixing the recombinant polypeptide with red blood cells and anti-coronavirus antibodies resulting in visible agglutination.

Provided herein are methods for detecting, monitoring, diagnosing and treating respiratory-related viral infections, including SARS-CoV-2 infected individuals and subjects that are infected with or suspected of having been infected with the virus, or that have come in contact with COVID-19 suffering individuals.

The present disclosure provides compositions and methods for treating and detecting coronavirus infection, and in particular embodiments, provides compositions and methods for treating and detecting SARS-CoV-2 infection. The present disclosure also relates to the production of compositions for treating and detecting coronavirus infection, and in particular embodiments, to the production of compositions for treating and detecting SARS-CoV-2 infection.

Methods of detecting presence of a virus in a sample are provided, the method including contacting the sample with a solid state nanopore comprising a plurality of virus-specific aptamers and measuring a current-voltage curve in the solid state nanopore, wherein a decrease in the current indicates presence of the virus in the sample. Solid state nanopores comprising a plurality of virus-specific aptamers covalently linked to the interior of the solid state nanopore are also provided. Membranes including a plurality of solid state nanopores including a plurality of covalently attached virus-specific aptamers and kits and systems with a membrane including a plurality of solid state nanopores including a plurality of covalently attached virus-specific aptamers are also provided.

A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.

The present disclosure is directed to antibodies binding to and neutralizing Venezuelan Equine Encephalitis Vims (VEEV) and methods for use thereof.

Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E7.sub.11-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.

Compositions for determining the efficacy and/or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and can be frozen. Upon thawing such cells are activated by exposure to a series of dilutions of a vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and/or potency.

The present invention relates to a novel porcine pestivirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Furthermore the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.

The invention relates to murine monoclonal antibodies corresponding to monoclonal antibodies secreted by cell lines of hybridomas denominated 3G8/C11 and 7G4/A12, and which react against the antigen M of hMPV. Said antibodies do not compete with each other for the binding site for binding to the antigen, nor do they impede the simultaneous binding thereof to the antigen. Said monoclonal antibodies can be used for tests for the detection, diagnosis and/or determination of infection by hMPV.